Terms: = Prostate cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
63 results:
1. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
Yamamichi G; Kato T; Yumiba S; Tomiyama E; Koh Y; Nakano K; Matsushita M; Hayashi Y; Ishizuya Y; Watabe T; Hatano K; Kawashima A; Ujike T; Ono Y; Takada T; Takada S; Imamura R; Nonomura N; Uemura M
Int J Urol; 2023 Jan; 30(1):70-76. PubMed ID: 36305578
[TBL] [Abstract] [Full Text] [Related]
3.
Metser U; Ortega C; Hussey D; Chan R; Berlin A; Finelli A; Veit-Haibach P
Curr Oncol; 2021 Aug; 28(5):3251-3258. PubMed ID: 34449586
[TBL] [Abstract] [Full Text] [Related]
4. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
5. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
Hansum T; Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Remmers S; van Leenders GJLH
Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
[TBL] [Abstract] [Full Text] [Related]
6. aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in
Nickols N; Anand A; Johnsson K; Brynolfsson J; Borreli P; Parikh N; Juarez J; Jafari L; Eiber M; Rettig M
J Nucl Med; 2022 Feb; 63(2):233-239. PubMed ID: 34049980
[TBL] [Abstract] [Full Text] [Related]
7. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients.
Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Roobol MJ; van Leenders GJLH
Mod Pathol; 2021 Jan; 34(1):184-193. PubMed ID: 32686748
[TBL] [Abstract] [Full Text] [Related]
8. Early prostate-Specific Antigen Changes and clinical outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract] [Full Text] [Related]
9. Early Post-treatment prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced prostate cancer: An International Collaborative Analysis.
Rescigno P; Dolling D; Conteduca V; Rediti M; Bianchini D; Lolli C; Ong M; Li H; Omlin AG; Schmid S; Caffo O; Zivi A; Pezaro CJ; Morley C; Olmos D; Romero-Laorden N; Castro E; Saez MI; Mehra N; Smeenk S; Sideris S; Gil T; Banks P; Sandhu SK; Sternberg CN; De Giorgi U; De Bono JS
Eur Urol Oncol; 2020 Apr; 3(2):176-182. PubMed ID: 31307958
[TBL] [Abstract] [Full Text] [Related]
10. miR-195 inhibits cell proliferation and angiogenesis in human prostate cancer by downregulating PRR11 expression.
Cai C; He H; Duan X; Wu W; Mai Z; Zhang T; Fan J; Deng T; Zhong W; Liu Y; Zhong W; Zeng G
Oncol Rep; 2018 Apr; 39(4):1658-1670. PubMed ID: 29393495
[TBL] [Abstract] [Full Text] [Related]
11. Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis.
Lancia A; Ingrosso G; Carosi A; Di Murro L; Giudice E; Cicchetti S; Morelli P; di Cristino D; Bruni C; Murgia A; Cancelli A; Turturici I; Iadevaia A; Ponti E; Santoni R
Acta Oncol; 2017 Nov; 56(11):1621-1625. PubMed ID: 28820285
[TBL] [Abstract] [Full Text] [Related]
12. Systematic Review of Immune Checkpoint Inhibition in Urological cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract] [Full Text] [Related]
13. High Dose Rate Brachytherapy as Monotherapy for Localised prostate cancer: Review of the Current Status.
Tselis N; Hoskin P; Baltas D; Strnad V; Zamboglou N; Rödel C; Chatzikonstantinou G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):401-411. PubMed ID: 28341241
[TBL] [Abstract] [Full Text] [Related]
14. Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer.
Franzese C; Fogliata A; D'Agostino GR; Di Brina L; Comito T; Navarria P; Cozzi L; Scorsetti M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1301-1309. PubMed ID: 28271215
[TBL] [Abstract] [Full Text] [Related]
15. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and clinical outcome in Patients with Castration-Resistant prostate cancer.
Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
[TBL] [Abstract] [Full Text] [Related]
16. Systemic Radioligand Therapy with (177)Lu Labeled prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant prostate cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract] [Full Text] [Related]
17. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant prostate cancer Pretreated With Docetaxel Chemotherapy: A prostate cancer clinical Trial Consortium Study.
Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
[TBL] [Abstract] [Full Text] [Related]
18. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion.
Nolan KD; Franco OE; Hance MW; Hayward SW; Isaacs JS
J Biol Chem; 2015 Mar; 290(13):8271-82. PubMed ID: 25670862
[TBL] [Abstract] [Full Text] [Related]
19. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.
Jacobs C; Tumati V; Kapur P; Yan J; Hong D; Bhuiyan M; Xie XJ; Pistenmaa D; Yu L; Hsieh JT; Saha D; Kim DW
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):729-35. PubMed ID: 24867541
[TBL] [Abstract] [Full Text] [Related]
20. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract] [Full Text] [Related]
[Next]
